Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study
Abstract Introduction We aim to assess the association of patient-reported pain and remission or low disease activity (LDA) at 3 months (M) in patients receiving baricitinib or other treatments in RA-BE-REAL. Methods RA-BE-REAL reports on patients with rheumatoid arthritis (RA) who were prescribed,...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-12-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-024-00732-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585391277867008 |
|---|---|
| author | Peter C. Taylor Walid Fakhouri Samuel Ogwu Ewa Haladyj Inmaculada de la Torre Bruno Fautrel Rieke Alten Peter Nash Eugen Feist |
| author_facet | Peter C. Taylor Walid Fakhouri Samuel Ogwu Ewa Haladyj Inmaculada de la Torre Bruno Fautrel Rieke Alten Peter Nash Eugen Feist |
| author_sort | Peter C. Taylor |
| collection | DOAJ |
| description | Abstract Introduction We aim to assess the association of patient-reported pain and remission or low disease activity (LDA) at 3 months (M) in patients receiving baricitinib or other treatments in RA-BE-REAL. Methods RA-BE-REAL reports on patients with rheumatoid arthritis (RA) who were prescribed, for the first time, baricitinib (cohort A) or a tumour necrosis factor inhibitor (TNFi) (cohort B-TNFi) or any other mode of action (OMA) (cohort B-OMA). Pain was measured using the visual analogue scale (VAS) (0–100 mm) and clinically meaningful pain improvement thresholds of ≥ 30%, ≥ 50% and ≥ 70% from baseline to 3, 6, 12 and 24 M. Results At 3 M, the mean change from baseline (CFB) pain VAS of patients in remission/LDA was − 32.6 mm (cohort A), − 27.3 mm (cohort B-TNFi) and − 28.0 mm (cohort B-OMA). Almost half the patients who were in remission/LDA receiving baricitinib achieved ≥ 70% pain relief. At 3 M, the proportion of patients in remission/LDA with pain VAS ≤ 20 mm was 62.1% (cohort A), 55.0% (cohort B-TNFi) and 55.6% (cohort B-OMA), while for those not in remission/LDA, it was 8.5% and 8.7% (cohort A and B-TNFi, respectively) and 5.3% (B-OMA). More patients on baricitinib achieved pain improvement in all analyzed thresholds than patients in cohort B-TNFi and B-OMA at 3 M. At 24 M, − 26.2 mm (cohort A), − 20.8 mm (cohort B-TNFi) and − 16.0 mm (cohort B-OMA) mean CFBs in pain measurement were observed. For baricitinib and the other treatments, residual pain decreased with achievement of remission/LDA and was sustained up to 24 M. Conclusions Patients in remission/LDA receiving baricitinib are more likely to achieve pain control than patients receiving TNFi/OMA. |
| format | Article |
| id | doaj-art-e36bac04966a41f283302e485cff3414 |
| institution | Kabale University |
| issn | 2198-6576 2198-6584 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj-art-e36bac04966a41f283302e485cff34142025-01-26T12:52:05ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842024-12-0112110912210.1007/s40744-024-00732-8Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational StudyPeter C. Taylor0Walid Fakhouri1Samuel Ogwu2Ewa Haladyj3Inmaculada de la Torre4Bruno Fautrel5Rieke Alten6Peter Nash7Eugen Feist8Botnar Research Centre, Nuffield Department of Orthopaedics, Rhematology and Musculoskeletal Sciences, University of OxfordEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyDepartment of Rheumatology, Assistance Publique Hospitaux de Paris, Pitie Salpetriere Hospital, Sorbonne UniversityDepartment of Internal Medicine and Rheumatology, Schlosspark KlinikSchool of Medicine, Griffith UniversityDepartment of Rheumatology, Helios ClinicAbstract Introduction We aim to assess the association of patient-reported pain and remission or low disease activity (LDA) at 3 months (M) in patients receiving baricitinib or other treatments in RA-BE-REAL. Methods RA-BE-REAL reports on patients with rheumatoid arthritis (RA) who were prescribed, for the first time, baricitinib (cohort A) or a tumour necrosis factor inhibitor (TNFi) (cohort B-TNFi) or any other mode of action (OMA) (cohort B-OMA). Pain was measured using the visual analogue scale (VAS) (0–100 mm) and clinically meaningful pain improvement thresholds of ≥ 30%, ≥ 50% and ≥ 70% from baseline to 3, 6, 12 and 24 M. Results At 3 M, the mean change from baseline (CFB) pain VAS of patients in remission/LDA was − 32.6 mm (cohort A), − 27.3 mm (cohort B-TNFi) and − 28.0 mm (cohort B-OMA). Almost half the patients who were in remission/LDA receiving baricitinib achieved ≥ 70% pain relief. At 3 M, the proportion of patients in remission/LDA with pain VAS ≤ 20 mm was 62.1% (cohort A), 55.0% (cohort B-TNFi) and 55.6% (cohort B-OMA), while for those not in remission/LDA, it was 8.5% and 8.7% (cohort A and B-TNFi, respectively) and 5.3% (B-OMA). More patients on baricitinib achieved pain improvement in all analyzed thresholds than patients in cohort B-TNFi and B-OMA at 3 M. At 24 M, − 26.2 mm (cohort A), − 20.8 mm (cohort B-TNFi) and − 16.0 mm (cohort B-OMA) mean CFBs in pain measurement were observed. For baricitinib and the other treatments, residual pain decreased with achievement of remission/LDA and was sustained up to 24 M. Conclusions Patients in remission/LDA receiving baricitinib are more likely to achieve pain control than patients receiving TNFi/OMA.https://doi.org/10.1007/s40744-024-00732-8BaricitinibRheumatoid arthritisRemissionLow disease activity |
| spellingShingle | Peter C. Taylor Walid Fakhouri Samuel Ogwu Ewa Haladyj Inmaculada de la Torre Bruno Fautrel Rieke Alten Peter Nash Eugen Feist Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study Rheumatology and Therapy Baricitinib Rheumatoid arthritis Remission Low disease activity |
| title | Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study |
| title_full | Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study |
| title_fullStr | Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study |
| title_full_unstemmed | Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study |
| title_short | Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study |
| title_sort | association between patient reported pain and remission or low disease activity in patients with rheumatoid arthritis data from ra be real prospective observational study |
| topic | Baricitinib Rheumatoid arthritis Remission Low disease activity |
| url | https://doi.org/10.1007/s40744-024-00732-8 |
| work_keys_str_mv | AT peterctaylor associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT walidfakhouri associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT samuelogwu associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT ewahaladyj associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT inmaculadadelatorre associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT brunofautrel associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT riekealten associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT peternash associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy AT eugenfeist associationbetweenpatientreportedpainandremissionorlowdiseaseactivityinpatientswithrheumatoidarthritisdatafromraberealprospectiveobservationalstudy |